What is Zofran (Ondansetron)?Lingual tablets are round, white, convex on one side and flat - on the other.
Mode of action - antiemetic.
Prevention and elimination of nausea and vomiting caused by the conduct of cytostatic chemotherapy or radiotherapy;
Prevention and elimination of postoperative nausea and vomiting.
Contraindications.Hypersensitivity to any component of the drug;
Children's age (suppositories);
Children under 2 years.
Zofran (Ondansetron) Side Effects.Allergic reactions: urticaria, bronchospasm, laryngospasm, angioedema, anaphylaxis.
Part of the digestive system: hiccups, dry mouth, constipation or diarrhea, burning sensation in the anus and rectum after administration of a suppository, and sometimes - asymptomatic transient elevation of liver tests.
Cardio-vascular system: chest pain, in some cases - with depression of segment ST, arrhythmia, bradycardia.
The nervous system: headache, dizziness, spontaneous movement disorders and seizures.
Other: flushing, hot flashes, temporary denial of visual acuity, hypokalemia, hypercreatininemia.
Dosage and administration Zofran (Ondansetron).The tablet for sucking on the tip of the tongue is placed after the dissolution of her swallow.
The choice of dosage regimen is determined emetogennostyu anticancer therapy.
Adults: daily dose, as a rule - 8-32 mg.
at a moderate emetogennoy chemotherapy and radiotherapy recommended dose - 8 mg Ondansetron for 1-2 hours before the start of primary therapy, followed by taking an additional 8 mg orally 12 hours;
with chemotherapy vysokoemetogennoy recommended dose - 24 mg ondansetron in conjunction with dexamethasone at a dose of 12 mg 1-2 hours before the start of chemotherapy.
For the prevention of late or prolonged vomiting that occurs after 24 hours, you should continue taking Zofran (Ondansetron) orally at a dose of 8 mg 2 times daily for 5 days.
Adults for the prevention of nausea and vomiting in the postoperative period is recommended 16 mg Zofran (Ondansetron) inside for 1 h prior to anesthesia.
Patients of advanced age. Changes in dosage is required.
Patients with renal insufficiency. No special changes in dosage, frequency of administration or method of application.
Patients with impaired liver function. Daily dose of Ondansetron should not exceed 8 mg.
Patients with a slow metabolism of sparteine / debrizohina. Adjustment of the daily dose or frequency of administration Ondansetron is not required.